These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 2563689)

  • 1. Debrisoquine oxidative phenotyping and psychiatric drug treatment.
    Derenne F; Joanne C; Vandel S; Bertschy G; Volmat R; Bechtel P
    Eur J Clin Pharmacol; 1989; 36(1):53-8. PubMed ID: 2563689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitory effects of neuroleptics on debrisoquine oxidation in man.
    Syvälahti EK; Lindberg R; Kallio J; De Vocht M
    Br J Clin Pharmacol; 1986 Jul; 22(1):89-92. PubMed ID: 2874826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Debrisoquine oxidation in schizophrenic patients treated with neuroleptics.
    Spina E; Buemi AL; Caputi AP; Benitez J; Cobaleda J; Garcia MA; Llerena A; Piña B
    Pharmacol Res Commun; 1988 Dec; 20(12):1103-4. PubMed ID: 2905478
    [No Abstract]   [Full Text] [Related]  

  • 4. Evidence for the polymorphic oxidation of debrisoquine in the Thai population.
    Wanwimolruk S; Patamasucon P; Lee EJ
    Br J Clin Pharmacol; 1990 Feb; 29(2):244-7. PubMed ID: 2306417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.
    Horai Y; Taga J; Ishizaki T; Ishikawa K
    Br J Clin Pharmacol; 1990 Jan; 29(1):111-5. PubMed ID: 2297455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetic covariation of defective N-oxidation of sparteine and 4-hydroxylation of debrisoquine.
    Bertilsson L; Dengler HJ; Eichelbaum M; Schulz HU
    Eur J Clin Pharmacol; 1980 Feb; 17(2):153-5. PubMed ID: 7371707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pharmacogenetics of antidepressant metabolism. Value of the debrisoquin test].
    Baumann P
    Encephale; 1986; 12(4):143-8. PubMed ID: 3792273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deficient metabolism of debrisoquine and sparteine.
    Inaba T; Otton SV; Kalow W
    Clin Pharmacol Ther; 1980 Apr; 27(4):547-9. PubMed ID: 7357813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diurnal effects on debrisoquine hydroxylation phenotyping.
    Lee EJ
    Eur J Clin Pharmacol; 1988; 35(4):441-2. PubMed ID: 3197754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diazepam treatment does not influence the debrisoquine or mephenytoin hydroxylation phenotyping tests.
    Spina E; Buemi AL; Sanz E; Bertilsson L
    Ther Drug Monit; 1989 Nov; 11(6):721-3. PubMed ID: 2595755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Debrisoquine oxidation in a Finnish population: the effect of oral contraceptives on the metabolic ratio.
    Kallio J; Lindberg R; Huupponen R; Iisalo E
    Br J Clin Pharmacol; 1988 Dec; 26(6):791-5. PubMed ID: 3242585
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphism of debrisoquine 4-hydroxylation and family studies of poor metabolizers in Chinese population.
    Du YL; Lou YQ
    Zhongguo Yao Li Xue Bao; 1990 Jan; 11(1):7-10. PubMed ID: 2403020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetically determined oxidation capacity and the disposition of debrisoquine.
    Sloan TP; Lancaster R; Shah RR; Idle JR; Smith RL
    Br J Clin Pharmacol; 1983 Apr; 15(4):443-50. PubMed ID: 6849780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants.
    Bertilsson L; Aberg-Wistedt A; Gustafsson LL; Nordin C
    Ther Drug Monit; 1985; 7(4):478-80. PubMed ID: 4082245
    [No Abstract]   [Full Text] [Related]  

  • 15. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.
    Eichelbaum M; Bertilsson L; Säwe J; Zekorn C
    Clin Pharmacol Ther; 1982 Feb; 31(2):184-6. PubMed ID: 7056024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients--relationship to the debrisoquine hydroxylation metabolic ratio.
    Nordin C; Siwers B; Benitez J; Bertilsson L
    Br J Clin Pharmacol; 1985 Jun; 19(6):832-5. PubMed ID: 4027124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of the sparteine/debrisoquine oxidation polymorphism.
    Brøsen K; Gram LF
    Eur J Clin Pharmacol; 1989; 36(6):537-47. PubMed ID: 2570698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphism of the 4-hydroxylation of debrisoquine in the San Bushmen of southern Africa.
    Sommers DK; Moncrieff J; Avenant J
    Hum Toxicol; 1988 May; 7(3):273-6. PubMed ID: 3391625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism.
    Brøsen K; Klysner R; Gram LF; Otton SV; Bech P; Bertilsson L
    Eur J Clin Pharmacol; 1986; 30(6):679-84. PubMed ID: 3533565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The metabolism of debrisoquine in man: (1) regioselectivity of hydroxylation and (2) aberrant oxidative metabolism in two sibling patients with carbimazole-induced agranulocytosis.
    Ritchie JC; Crothers MJ; Shah RR; Idle JR; Smith RL
    Xenobiotica; 1986 May; 16(5):503-9. PubMed ID: 3739370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.